Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × Adrenal Cortex Hormones × Clear all

NCT05660421 2024-10-31

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Phase 2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms